Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
GAITHERSBURG, Md., June 18 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that, in connection with the closing of the acquisition of MedImmune by AstraZeneca PLC pursuant to a...
Biotechnology Company Honored for Internal Launch of Productivity Tracking System GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that the company was...
- 10th Consecutive Year for MedImmune on the Fast 50 List - GAITHERSBURG, Md., Sept. 29 /PRNewswire-FirstCall/ -- MedImmune, Inc. has been named to Deloitte's Maryland Technology Fast 50 program...
GAITHERSBURG, Md., Oct. 12 /PRNewswire-FirstCall/ -- MedImmune, Inc. has been named to Deloitte's Maryland Technology Fast 50 program for the ninth consecutive year. The Technology Fast 50 is a...
Standard & Poor's Announces Semi-Annual Reconstitution of Standard & Poor's/Barra Growth and Value Indices NEW YORK, Dec. 10 /PRNewswire/ -- Standard & Poor's will make its semi-annual changes...
Data Show Ethyol(R) Reduces Radiation Therapy-Induced Dry Mouth in Head and Neck Cancer Patients For 24 Months NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Data presented today from a Phase 3...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.85 | 1.85 | 1.85 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.85 | 1.85 | 1.85 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.85 | 1.85 | 1.85 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.85 | 1.85 | 1.85 | 0 | 0 | CS |
| 52 | 0 | 0 | 1.85 | 1.85 | 1.85 | 0 | 0 | CS |
| 156 | 0 | 0 | 1.85 | 1.85 | 1.85 | 0 | 0 | CS |
| 260 | -4.65 | -71.5384615385 | 6.5 | 6.5 | 0.26 | 2491 | 1.14491134 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
